Bence Patocskai1, Hector Barajas-Martinez2, Dan Hu2, Zsolt Gurabi1, István Koncz1, Charles Antzelevitch3. 1. Masonic Medical Research Laboratory, Utica, New York; Department of Pharmacology and Pharmacotherapy, University of Szeged, Szeged, Hungary. 2. Masonic Medical Research Laboratory, Utica, New York. 3. Lankenau Institute for Medical Research, Wynnewood, Pennsylvania. Electronic address: barajash@mmrl.edu.
Abstract
BACKGROUND: Early repolarization syndrome (ERS) is associated with polymorphic ventricular tachycardia (PVT) and ventricular fibrillation, leading to sudden cardiac death. OBJECTIVE: The present study tests the hypothesis that the transient outward potassium current (Ito)-blocking effect of phosphodiesterase-3 (PDE-3) inhibitors plays a role in reversing repolarization heterogeneities responsible for arrhythmogenesis in experimental models of ERS. METHODS: Transmembrane action potentials (APs) were simultaneously recorded from epicardial and endocardial regions of coronary-perfused canine left ventricular (LV) wedge preparations, together with a transmural pseudo-electrocardiogram. The Ito agonist NS5806 (7-15 μM) and L-type calcium current (ICa) blocker verapamil (2-3 μM) were used to induce an early repolarization pattern and PVT. RESULTS: After stable induction of arrhythmogenesis, the PDE-3 inhibitors cilostazol and milrinone or isoproterenol were added to the coronary perfusate. All were effective in restoring the AP dome in the LV epicardium, thus abolishing the repolarization defects responsible for phase 2 reentry and PVT. Arrhythmic activity was suppressed in 7 of 8 preparations by cilostazol (10 μM), 6 of 7 by milrinone (2.5 μM), and 7 of 8 by isoproterenol (0.1-1 μM). Using voltage clamp techniques applied to LV epicardial myocytes, both cilostazol (10 μM) and milrinone (2.5 μM) were found to reduce Ito by 44.4% and 40.4%, respectively, in addition to their known effects to augment ICa. CONCLUSION: Our findings suggest that PDE-3 inhibitors exert an ameliorative effect in the setting of ERS by producing an inward shift in the balance of current during the early phases of the epicardial AP via inhibition of Ito as well as augmentation of ICa, thus reversing the repolarization defects underlying the development of phase 2 reentry and ventricular tachycardia/ventricular fibrillation.
BACKGROUND: Early repolarization syndrome (ERS) is associated with polymorphic ventricular tachycardia (PVT) and ventricular fibrillation, leading to sudden cardiac death. OBJECTIVE: The present study tests the hypothesis that the transient outward potassium current (Ito)-blocking effect of phosphodiesterase-3 (PDE-3) inhibitors plays a role in reversing repolarization heterogeneities responsible for arrhythmogenesis in experimental models of ERS. METHODS: Transmembrane action potentials (APs) were simultaneously recorded from epicardial and endocardial regions of coronary-perfused canine left ventricular (LV) wedge preparations, together with a transmural pseudo-electrocardiogram. The Ito agonist NS5806 (7-15 μM) and L-type calcium current (ICa) blocker verapamil (2-3 μM) were used to induce an early repolarization pattern and PVT. RESULTS: After stable induction of arrhythmogenesis, the PDE-3 inhibitors cilostazol and milrinone or isoproterenol were added to the coronary perfusate. All were effective in restoring the AP dome in the LV epicardium, thus abolishing the repolarization defects responsible for phase 2 reentry and PVT. Arrhythmic activity was suppressed in 7 of 8 preparations by cilostazol (10 μM), 6 of 7 by milrinone (2.5 μM), and 7 of 8 by isoproterenol (0.1-1 μM). Using voltage clamp techniques applied to LV epicardial myocytes, both cilostazol (10 μM) and milrinone (2.5 μM) were found to reduce Ito by 44.4% and 40.4%, respectively, in addition to their known effects to augment ICa. CONCLUSION: Our findings suggest that PDE-3 inhibitors exert an ameliorative effect in the setting of ERS by producing an inward shift in the balance of current during the early phases of the epicardial AP via inhibition of Ito as well as augmentation of ICa, thus reversing the repolarization defects underlying the development of phase 2 reentry and ventricular tachycardia/ventricular fibrillation.
Authors: Peter W Macfarlane; Charles Antzelevitch; Michel Haissaguerre; Heikki V Huikuri; Mark Potse; Raphael Rosso; Frederic Sacher; Jani T Tikkanen; Hein Wellens; Gan-Xin Yan Journal: J Am Coll Cardiol Date: 2015-07-28 Impact factor: 24.094
Authors: Elena Burashnikov; Ryan Pfeiffer; Héctor Barajas-Martinez; Eva Delpón; Dan Hu; Mayurika Desai; Martin Borggrefe; Michel Häissaguerre; Ronald Kanter; Guido D Pollevick; Alejandra Guerchicoff; Ruben Laiño; Mark Marieb; Koonlawee Nademanee; Gi-Byoung Nam; Roberto Robles; Rainer Schimpf; Dwight D Stapleton; Sami Viskin; Stephen Winters; Christian Wolpert; Samuel Zimmern; Christian Veltmann; Charles Antzelevitch Journal: Heart Rhythm Date: 2010-10-14 Impact factor: 6.343
Authors: José M Di Diego; Serge Sicouri; Rachel C Myles; Francis L Burton; Godfrey L Smith; Charles Antzelevitch Journal: J Mol Cell Cardiol Date: 2012-11-09 Impact factor: 5.000
Authors: John R Giudicessi; Dan Ye; Chad J Kritzberger; Vladislav V Nesterenko; David J Tester; Charles Antzelevitch; Michael J Ackerman Journal: Hum Mutat Date: 2012-03-27 Impact factor: 4.878
Authors: David S Park; Marina Cerrone; Gregory Morley; Carolina Vasquez; Steven Fowler; Nian Liu; Scott A Bernstein; Fang-Yu Liu; Jie Zhang; Christopher S Rogers; Silvia G Priori; Larry A Chinitz; Glenn I Fishman Journal: J Clin Invest Date: 2014-12-15 Impact factor: 14.808
Authors: Dan Hu; Hector Barajas-Martínez; Andre Terzic; Sungjo Park; Ryan Pfeiffer; Elena Burashnikov; Yuesheng Wu; Martin Borggrefe; Christian Veltmann; Rainer Schimpf; John J Cai; Gi-Byong Nam; Pramod Deshmukh; Melvin Scheinman; Mark Preminger; Jonathan Steinberg; Angélica López-Izquierdo; Daniela Ponce-Balbuena; Christian Wolpert; Michel Haïssaguerre; José Antonio Sánchez-Chapula; Charles Antzelevitch Journal: Int J Cardiol Date: 2014-01-04 Impact factor: 4.164
Authors: Mark J Perrin; Arnon Adler; Sharon Green; Foad Al-Zoughool; Petro Doroshenko; Nathan Orr; Shaheen Uppal; Jeff S Healey; David Birnie; Shubhayan Sanatani; Martin Gardner; Jean Champagne; Chris Simpson; Kamran Ahmad; Maarten P van den Berg; Vijay Chauhan; Peter H Backx; J Peter van Tintelen; Andrew D Krahn; Michael H Gollob Journal: Circ Cardiovasc Genet Date: 2014-09-11
Authors: Raphael Rosso; Evgeni Kogan; Bernard Belhassen; Uri Rozovski; Melvin M Scheinman; David Zeltser; Amir Halkin; Arie Steinvil; Karin Heller; Michael Glikson; Amos Katz; Sami Viskin Journal: J Am Coll Cardiol Date: 2008-10-07 Impact factor: 24.094
Authors: Eva Delpón; Jonathan M Cordeiro; Lucía Núñez; Poul Erik Bloch Thomsen; Alejandra Guerchicoff; Guido D Pollevick; Yuesheng Wu; Jørgen K Kanters; Carsten Toftager Larsen; Jacob Hofman-Bang; Elena Burashnikov; Michael Christiansen; Charles Antzelevitch Journal: Circ Arrhythm Electrophysiol Date: 2008-08
Authors: Felix Bourier; Arnaud Denis; Ghassen Cheniti; Anna Lam; Konstantinos Vlachos; Masateru Takigawa; Takeshi Kitamura; Antonio Frontera; Josselin Duchateau; Thomas Pambrun; Nicolas Klotz; Nicolas Derval; Frédéric Sacher; Pierre Jais; Michel Haissaguerre; Mélèze Hocini Journal: Front Cardiovasc Med Date: 2018-11-27
Authors: Ben N Mercer; Gordon A Begg; Stephen P Page; Christopher P Bennett; Muzahir H Tayebjee; Saagar Mahida Journal: Front Physiol Date: 2016-06-30 Impact factor: 4.566
Authors: Wener Li; Michael Stauske; Xiaojing Luo; Stefan Wagner; Meike Vollrath; Carola S Mehnert; Mario Schubert; Lukas Cyganek; Simin Chen; Sayed-Mohammad Hasheminasab; Gerald Wulf; Ali El-Armouche; Lars S Maier; Gerd Hasenfuss; Kaomei Guan Journal: Front Cell Dev Biol Date: 2020-10-22